BIOPTEQ
ActiveBIOPTEQ has been active since 2005 and the Belgian State Gazette contains no insolvency or warning signals. The 2024 annual accounts show equity of €816k and a net result of €54k. Equity is growing by ~4.2% per year across the filed fiscal years. Its solvency ranks better than 91% of 242 sector peers (fiscal year 2024). The computed 12-month bankruptcy probability is 0.3% (very low).
Checked score
Score 2024
90
/ 100
Excellent
The score weighs solvency, liquidity and profitability. Bankruptcy probability contributes 35%. Every signal that weighs is under Signals.
Axes · tick = 2023
Profitability76=
Solvency100=
Growth46=
Track record100
Bankruptcy probability, 12 months
0.3%
Very low
0%0.5%1.5%4%10%≥ 25%
Credit up to €70k at 30 days acceptable
Liquidity ample (current ratio 13.23 against 23.98 in 2023; short-term debt: 7.1% and cash: 57.9% of total assets), and 7.2% of the assets are financed with debt.
Credit advice for your own amount and term
Signals
Six signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
lowers risk · Lower-failure-rate sector
In this sector companies fail less often than the Belgian average.
Gazette · bankruptcies per sector, NACE 72
Relative position
BE, all sectors
reference
Sector 72
lower
← fewer bankruptcies
more bankruptcies →
lowers risk · Long track record
A company with a long track record statistically fails less often than a young one.
KBO · incorporation dateAge against the risk zone
lowers risk · Annual accounts: healthy financial profile
The latest annual accounts show a healthy profile in solvency, result and liquidity.
NBB · annual accounts 2024Solvency, return and age of the figures
Solvency
92.8%
Return on assets
6.1%
Age of the figures
21 mo
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2024 was due by 31-07-2025 and was filed on 04-06-2025, 57 days ahead of the deadline.
NBB · 10 filingsDeviation from the deadline
2025
not confirmed
2024
57 d early
2023
79 d early
2022
74 d early
2021
76 d early
2020
60 d early
2019
57 d early
← before the deadline
after the deadline →
Financials · fiscal year 2024, full schema
Turnover
€254k▲ 39.0%
2021 · €183k
2018: €251k
2019: €195k
2020: €150k
2021: €183k
2018 → 2022
EBIT margin
44.9%▲ 18.9pp
2021 · 26.0%
2018: 67.5%
2019: 7.6%
2020: 2.0%
2021: 26.0%
2018 → 2022
Net result
€54k▲ 11.9%
2023 · €48k
2018: €118k
2019: €11k
2020: €472
2021: €36k
2022: €80k
2023: €48k
2018 → 2024
Working capital
€763k▲ 8.4%
2023 · €704k
2018: €577k
2019: €586k
2020: €520k
2021: €566k
2022: €657k
2023: €704k
2018 → 2024
Multi-year overview
Every figure with its change against the year before
▲ rise
▼ fall
Line20202021202220232024Trend
Turnover€150k-€183k▲ 21.7%€254k▲ 39.0%
Equity€598k-€635k▲ 6.1%€715k▲ 12.6%€763k▲ 6.7%€816k▲ 7.0%
Operating result€3k-€47k▲ 1,445%€114k▲ 140%€67k▼ 41.2%€72k▲ 7.1%
Net result€472-€36k▲ 7,598%€80k▲ 120%€48k▼ 40.1%€54k▲ 11.9%
Result per fiscal year
Operating resultNet result
The operating result recovers in 2024; 2024 is 7% above 2023.
Balance-sheet composition
2024 in colour, 2023 as the grey bar beneath
Assets €879k
Fixed assets
€53k▼ 9.2%
Current assets
€826k▲ 12.4%
Equity and liabilities €879k
Equity
€816k▲ 7.0%
Debt
€63k▲ 102%
The debt ratio rises from 3.9% to 7.2%. Equity and debt are higher.
Key figures and ratios
EBITDA
€77k▲
2023 · €74k
Cash flow
€59k▲
2023 · €55k
Solvency
92.8%▼
2023 · 96.1%
Current ratio
13.23▼
2023 · 23.98
Quick ratio
13.23▼
2023 · 23.98
Debt / equity
0.08▲
2023 · 0.04
ROE
6.6%▲
2023 · 6.3%
ROA
6.1%▲
2023 · 6.0%
Interest coverage
804.23▲
2023 · 60.56
Debt
€63k▲
2023 · €31k
Debt ≤ 1 year
€62k▲
2023 · €31k
Income taxes
€22k▲
2023 · €19k
Staff costs
€17k▲
2023 · €15k
Green means a favourable move, even when the figure itself falls: as with debt or debt / equity.
Filed annual accounts
As filed with the NBB · 2024 against 2023
Balance sheet
Code20232024
Assets
Total assets20/58€794k€879k▲
Fixed assets21/28€59k€53k▼
Intangible fixed assets21€916-
Tangible fixed assets22/27€8k€4k▼
Furniture and vehicles24€7k€4k▼
Other tangible fixed assets26€946€249▼
Financial fixed assets28€50k€50k=
Current assets29/58€735k€826k▲
Amounts receivable within one year40/41€299k€315k▲
Trade receivables40€297k€315k▲
Other amounts receivable41€2k-
Cash at bank and in hand54/58€433k€509k▲
Deferred charges and accrued income490/1€2k€2k▼
Equity and liabilities
Total equity and liabilities10/49€794k€879k▲
Equity10/15€763k€816k▲
Contributions10/11€6k€6k=
Reserves13€127k€185k▲
Non-distributable reserves130/1€127k-
Reserves not available under the articles1311€127k-
Distributable reserves133-€185k
Profit (loss) carried forward14€630k€625k▼
Amounts payable17/49€31k€63k▲
Amounts payable within one year42/48€31k€62k▲
Trade debts44€2k€477▼
Suppliers440/4€2k€477▼
Taxes, remuneration and social security45€29k€62k▲
Taxes450/3€26k€57k▲
Remuneration and social security454/9€2k€5k▲
Accrued charges and deferred income492/3€489€515▲
Income statement
Code20232024
Remuneration, social security and pensions62€15k€17k▲
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€7k€5k▼
Other operating charges640/8€2k€2k▼
Non-recurring operating charges66A-€2
Gross operating margin9900€92k€96k▲
Operating profit (loss)9901€67k€72k▲
Financial income75/76B€1k€4k▲
Recurring financial income75€1k€4k▲
Financial charges65/66B€1k€96▼
Recurring financial charges65€1k€96▼
Profit (loss) for the period before taxes9903€67k€76k▲
Income taxes67/77€19k€22k▲
Profit (loss) for the period9904€48k€54k▲
Profit (loss) for the period to be appropriated9905€48k€54k▲
Appropriation of the result
Profit (loss) to be appropriated9906€676k€683k▲
Profit (loss) brought forward from the previous period14P€628k€630k▲
Transfer to equity691/2€46k€58k▲
To other reserves6921€46k€58k▲
The notes to these accounts (9 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.
Timeline · acts, filings and financial milestones
2025
04-06
NBB filing
Annual accounts filed
fiscal year 2024 · full schema
2024
13-05
NBB filing
Annual accounts filed
fiscal year 2023 · full schema
2023
18-05
NBB filing
Annual accounts filed
fiscal year 2022 · full schema
2022
16-05
NBB filing
Annual accounts filed
fiscal year 2021 · full schema
2021
31-12
Financial
Liquidity doublescurrent ratio 26.44
Current ratio from 12.34 to 26.44; short-term debt falls from €46k to €22k.
01-06
NBB filing
Annual accounts filed
fiscal year 2020 · full schema
2020
31-12
Financial
Weakest financial yearnet €472 ▼95.6%
Net result drops to €472, the lowest in the series; recovery starts the following year.
04-06
NBB filing
Annual accounts filed
fiscal year 2019 · full schema
2019
07-06
NBB filing
Annual accounts filed
fiscal year 2018 · full schema
2018
16-05
NBB filing
Annual accounts filed
fiscal year 2017 · full schema
2017
13-04
NBB filing
Annual accounts filed
fiscal year 2016 · full schema
2016
31-05
NBB filing
Annual accounts filed
fiscal year 2015 · full schema
Financial milestoneNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
Directors · office · real estate
Directors
4 acts for this company are in the Belgian State Gazette, of which we have read 0. We have therefore not extracted its directors from those acts yet.
Location & real-estate footprint
Registered office, Nandrin · 1 establishment unit since 2005
Cannot be placed on the map
This address could not be matched to a point in the Belgian address register (BOSA BEST). The address below comes straight from the Crossroads Bank.
Rue des Martyrs 474550 NandrinGround area
1,091 m²
Building footprint
157 m²
Volume, LiDAR
702 m³
Parcel 61043B0107/00V000, Wallonia · tallest building 6.0 m, ±2 floors. Linked by address, not a title deed.
1 establishment unit
BIOPTEQ
since 20052.150.657.571
1 parcel
Wallonia
1
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 61043B0107/00V000 | Wallonia | 1,091 m² | 1 · 157 m² | 6.0 m · 2 fl. |
Linked by address, not proof of ownership
Methodology
via registered seat: 1
1 of 1 parcel with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Similar companies · same sector, comparable size
EUROFINS PHARMACEUTICAL PRODUCT TESTING BELGIUM
BE 0435.237.515
Brugge · Eq €816k
Inokura
BE 0424.658.872
Liège · Eq €808k
Normec Micro-Smedt
BE 0456.514.959
Herentals · Eq €808k
Dokter Alexandra Keersmaekers
BE 0859.670.913
Mol · Eq €832k
Collaborative Research for Energy SYstem Modeling
BE 0790.603.745
Brussel · Eq €833k
Of 1,178 companies in sector 72109 we hold annual accounts for 716. 467 are within a factor 10 of this equity.See the whole sector
Company data · Crossroads Bank
Identification
Legal formPrivate limited company
Founded07-12-2005
Fiscal year end31-12
Activities, NACEBEL
72109Other research and development on natural sciences
73100
74909Other professional, scientific and technical activities
74999Other professional, scientific and technical activities
70200Business and other management consultancy
70220Business consulting
74142
Sources
Crossroads Bank for EnterprisesNational Bank · 19 filingsAddress and cadastre registers
Data from official sources, last processed on 17-09-2026. Scores and ratios are computed by Checked and are not a credit decision.